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ABSTRACT: 
Objectives: 
Cross-sectional imaging is now recommended by the National Institute for 
Health and Care Excellence (NICE) for patients with suspected and newly 
diagnosed myeloma instead of skeletal survey. The objectives of this study 
were:- 
1: To evaluate compliance of current UK imaging practice with reference to 
national NICE best-practice clinical guidelines for plasma cell malignancies. 
2:  To identify factors which may influence diagnostic imaging choices. 
Methods: 
We conducted a national online survey to assess compliance with guidelines and 
to identify challenges to implementation (endorsed by Myeloma UK, UK 
Myeloma Forum and the British Society of Skeletal Radiologists).  
Results: 
Responses were received from 31 district general and 28 teaching hospitals. For 
suspected and confirmed myeloma, skeletal survey remained the most frequent 
first-line imaging test (suspected myeloma 44.3%, confirmed myeloma 37.7%). 
Only 9.8% of responders offered first-line whole body magnetic resonance 
imaging.  
Conclusions: 
Significant challenges remain to standardisation of imaging practice in 
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accordance with national best-practice guidelines.  
Advances in Knowledge: 
This is the first publication to date evaluating current UK imaging practice for 
assessing myeloma since the publication of new guidelines recommending use of 
advanced cross-sectional imaging techniques. Skeletal survey remains the most 
commonly performed first-line imaging test in patients with suspected or 
confirmed myeloma and this is largely due to resource limitations within 
radiology departments. 
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INTRODUCTION: 
Whole body magnetic resonance imaging (WB-MRI) or whole body CT (WB-CT) 
or 18F-fluorodeoxyglucose positron emission tomography/computed 
tomography (18F-FDG PET/CT) are now recommended by the National Institute 
for Health and Care Excellence [NICE 2016, NG 351] and the British Society of 
Haematology [2017 guidelines2] for evaluating patients with suspected and 
newly diagnosed myeloma and solitary plasmacytoma. Current International 
Myeloma Working Group guidelines include the detection of greater than one 
unequivocal bone lesion on MRI (> 5 mm) or one or more lytic bone lesion 
detected on CT scan, including WB-CT or 18F-FDG PET/CT, as sufficient to fulfill 
the criteria for myeloma-defining bone disease3. NICE guidelines state that WB-
MRI (or WB-CT if patient declines or is unsuitable for MRI) should be considered 
as the first-line imaging test in patients with suspected myeloma. In patients 
with confirmed newly diagnosed myeloma, WB-MRI, WB-CT or 18F-FDG PET/CT 
should be considered to assess for myeloma-related bone disease and 
extramedullary plasmacytomas1. These guidelines acknowledge research 
showing that skeletal survey (SS) is inferior to WB-MRI, WB-CT or 18F-FDG 
PET/CT in the detection of myeloma related bone disease4. Thus SS, the former 
gold standard imaging test, should only be considered in suspected myeloma if 
WB-MRI or WB-CT is unsuitable or declined by the patient. We hypothesized that 
there may be significant regional variations in imaging practice despite best-
practice recommendations. 
 
METHODS: 
We conducted an online survey of myeloma imaging practice between 01 
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September and 31 October 2017, endorsed by Myeloma UK, UK Myeloma Forum 
and the British Society of Skeletal Radiologists. This was publicised to their 
members via an online link. Participants comprised both clinical haematologists 
and radiologists with an interest in plasma cell malignancies. Participants 
recorded the preferred first-line imaging test for suspected myeloma, confirmed 
new myeloma and solitary plasmacytoma for their institution. Participants were 
also asked to rank the order of preference for SS, WB-CT, MRI whole spine, WB-
MRI and 18-F FDG PET/CT in baseline imaging for suspected and confirmed 
myeloma and plasmacytoma at their institution. We sought information 
regarding institution type (district general hospital (DGH) or teaching hospital 
(TH)). Local challenges to implementing a WB-MRI or 18F-FDG PET/CT service 
were also explored. The questionnaire is shown in Figure 1. 
 
RESULTS: 
There were 67 responses. Following removal of duplicates there were responses 
from 31 district general hospitals, 28 teaching hospitals and 2 unconfirmed sites. 
For suspected and confirmed myeloma, SS remained the most commonly 
performed first-line imaging test; suspected myeloma 44.3% (15 DGH, 11 TH); 
confirmed myeloma 37.7% (12 DGH, 11 TH), followed by WB-CT; suspected 
myeloma 29.5% (11 DGH, 7 TH); confirmed myeloma 26.2% (9 DGH, 7 TH). 
Skeletal survey was also the preferred first-line imaging test at teaching 
hospitals. Only 9.8% of participants reported that WB-MRI was the preferred 
first-line imaging test at their institution for suspected and confirmed myeloma 
(suspected myeloma: 5 TH, 1 DGH; confirmed myeloma: 4 TH, 2 DGH).  
6 
 
For plasmacytoma, 18F-FDG PET/CT was the preferred first-line imaging test 
overall at 36.1% (15 DGH, 6 TH) followed by SS at 26.2% (7 DGH, 8 TH). WB-MRI 
and WB-CT were the preferred first-line imaging tests in plasmacytoma in 9.8% 
(6/61) and 16.4% (10/61) of institutions respectively.  
For confirmed myeloma 18F-FDG PET/CT was the preferred first-line imaging 
test in 14.8% (9/61 institutions). For confirmed myeloma and plasmacytoma, a 
greater proportion of district general hospitals performed 18F-FDG PET/CT as 
the first-line imaging test compared with teaching hospitals (confirmed myeloma 
6 DGH, 2 TH, 1 unknown institution type; plasmacytoma 15 district general 
hospital, 6 teaching hospitals). 18F-FDG PET/CT was not performed in suspected 
myeloma.  
46.4% of responders offered 18F-FDG PET/CT at their institution. Where 18F-
FDG PET/CT was not available, the commonest reported challenges were 
financial (26.8%) and scanner availability (14.3%). Only 16.4% of responders 
offered WB-MRI, with a slightly greater proportion of teaching hospitals, and 
only 9.8% as a first-line imaging test. The commonest reported challenges to 
implementing a WB-MRI service were scanner availability (66.7%), dedicated 
reporting time (66.7%), financial constraints (54.0%) and availability of 
radiologists trained to report WB-MRI (54.0%). Results are displayed in Figure 2. 
 
DISCUSSION: 
WB-MRI is now recognised by NICE as the gold standard imaging test for 
suspected myeloma due to its superior sensitivity in the detection of myeloma 
related bone disease5. It enables accurate documentation of pattern and extent of 
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disease. It detects bone marrow involvement prior to cortical destruction.  
Studies have demonstrated that WB-MRI has a greater sensitivity and specificity 
for detection of focal bone lesions in myeloma compared with both WB-CT 
(n=41)6 and 18F-FDG PET/CT (n=22)7.  
A standard WB-MRI protocol includes a T1-weighted and diffusion-weighted 
sequence (or short tau inversion recovery (STIR) sequence, if this is not 
possible) from the vertex to knees. A T1-weighted sequence following 
gadolinium contrast-administration improves sensitivity for bone lesion 
detection8 and should be considered in patients with adequate renal function. A 
T2-weighted sequence may augment assessment of extraosseous disease and 
complications of bone disease such as vertebral compression fractures and 
cord/cauda equina compression. A WB-MRI example is shown in Figure 3. 
Diffusion-weighted imaging performed as part of a WB-MRI examination, depicts 
the free diffusion/random motion of water molecules, which differs between 
fatty marrow and areas with plasma cell infiltration. Thus DWI sequences are 
sensitive for both focal and diffuse patterns of bone marrow infiltration9. In 
particular, DWI improves WB-MRI detection of rib lesions, previously 
challenging to assess at MRI, however sensitivity for detection of skull lesions 
remains inferior to SS, likely secondary to high background brain diffusion 
signal10.  
Nevertheless our survey found poor compliance with NICE guidance. Only 16.4% 
of responders offered WB-MRI and only 9.8% as the first-line imaging test in 
suspected or confirmed myeloma. Current rising healthcare demands and 
financial constraints coupled with national radiologist shortages are clear 
8 
 
underlying contributory factors to the current imaging landscape. The three 
commonest stated challenges were scanner capacity, reporting time and 
radiologists trained to report WB-MRI.  
The average duration of a WB-MRI scan is 45 minutes11 thus requiring a 
scheduled appointment of at least an hour. MRI scanner capacity and scanner 
capability will be an issue for most NHS hospitals. However with 5,540 new 
diagnoses per year in the UK (Cancer Research UK12), the number of newly 
diagnosed patients per hospital site per annum will be relatively small in 
comparison to other tumour types, for example, lung (46,388 new 
diagnoses/year12) and colorectal cancer (41,804 new diagnoses per year12) 
where WB-MRI is being considered for initial staging13. 
In terms of reporting, an experienced radiologist trained in WB-MRI will take an 
average of 30 minutes to report an examination, although the reporting time will 
vary according to experience and the number of comparative WB-MRI 
examinations. There are training courses available for WB-MRI in the UK 
however capacity again is an issue.  If NICE guidance is to be implemented 
successfully nationally, this will have to be addressed.  
WB-CT was the second preferred first-line imaging test for suspected and 
confirmed myeloma in our survey. A non-contrast WB-CT is quick to perform 
and is well tolerated by patients. The radiation dose for a very low dose protocol 
approaches that of SS with new iterative reconstructions (2.5 mSv approx. SS 
dose for 70 kg patient)2. Additional to the detection of osteolytic lesions, WB-CT 
can assess vertebral fractures, spinal stability and may be used in operative 
planning.  
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Evaluation of soft tissue involvement, retropulsion and spinal canal impingement 
is inferior to MRI, the imaging gold standard for spinal cord assessment. Only 
one study to date has compared the diagnostic performance of WB-CT with WB-
MRI in myeloma (n=41), where WB-MRI detected a greater number of lesions, 
upstaging 11 patients6. NICE guidelines state that WB-CT should be considered 
as an alternative in patients with asymptomatic myeloma and suspected 
myeloma where WB-MRI is not available/unsuitable.  Figure 4 demonstrates a 
multifocal pattern of bone disease on whole body CT in a patient with relapsed 
myeloma. 
Dual energy CT (DECT), where imaging is obtained at two distinct kilovolt peaks, 
improves the sensitivity of standard WB-CT for detection of bone marrow 
infiltration (standard WBCT = 69.6% sensitivity, virtual noncalcium (VNCa) 
technique = 91.3%, n = 34)14. Using a technique based on the principles of the 
virtual noniodine technique, DECT can generate an automated virtual 
noncalcium map, whereby trabeculated bone is subtracted from the bone 
marrow. Furthermore, in a recent study comparing DECT with MRI in 34 
patients with MGUS or myeloma, Kosmala et al. by using tin filtration, were able 
to separate yellow marrow from nonfat-containing soft tissue, thus highlighting 
potential regions of bone marrow replacement14. Important considerations 
affecting adoption of this technique include availability of DECT scanners, 
variations in scanner type, physicist support and radiation dose (mean volume 
CT dose index for WB-DECT = 9.7 +/- 4.3 mGy)14. Further studies are required 
comparing the sensitivity and specificity of WB-CT +/-DECT component 
compared with WB-MRI in detection of bone disease in myeloma. 
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The sensitivity of 18F-FDG PET/CT for detection of focal bone lesions is similar 
to WB-MRI however WB-MRI is more sensitive in the detection of diffuse and 
variegated disease patterns15. In response assessment/ detection of relapse, 18F-
FDG PET/CT has a clear role, distinguishing between active and inactive 
myeloma (meta-analysis, n=69016). 18F-FDG PET/CT has also been shown to 
have prognostic value in myeloma. In a study by Zagmani et al.17, both 
progression-free and overall survival were adversely affected by the presence of 
extramedullary disease, three or more focal lesions at baseline and an SUVmax  
greater than 4.2. An additional benefit of 18F-FDG is that is safe to use in patients 
with renal impairment. The choice of 18-F FDG PET/CT in this survey likely 
reflects easier access to centralised PET services for DGHs.  
18F-FDG is currently the only recommended radiopharmaceutical for clinical 
imaging in myeloma however it is recognised that approximately 11% of 
patients with myeloma do not have FDG avid disease18. Suggested underlying 
mechanisms for this include reduced expression of the enzyme hexokinase-2, 
involved in the first step of glucose metabolism18 and low volume plasma cell 
infiltration19. Alternative tracers such as choline may have improved sensitivity 
for detection of focal bone lesions in myeloma20. Choline is a cell membrane 
phospholipid precursor and therefore a marker of cell membrane turnover21. It 
is possible that increased choline utilization may precede increased glucose 
utilization in malignant plasma cells. Further research regarding the optimal 
radiopharmaceutical in myeloma imaging is needed. Figure 5 is a representative 
18F-FDG PET/CT image in a patient with multifocal pattern of myeloma. 
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Another issue not captured in our survey is that a significant minority of patients 
with suspected myeloma have a skeletal survey and then subsequently an 
advanced imaging technique. This pathway often makes the initial skeletal 
survey unnecessary and is the least cost-effective or patient-centered pathway. 
In view of this being current practice for a minority of patients, NICE felt that 
screening with WB-CT or WB-MRI alone (with no use of SS) in myeloma could be 
cost effective as long as screening was restricted to a population where myeloma 
was likely i.e. not patients with straightforward MGUS1. 
A limitation of this survey is that it only provides a snapshot of national imaging 
practices in myeloma and there may be local variations in practice that are not 
captured by our results. In the authors’ experience the results are thought to be 
broadly representative of current practice in this field.  
 
CONCLUSION: 
Whilst recent guidelines recommend that advanced imaging techniques should 
replace SS there is poor compliance nationally. Significant challenges remain to 
the standardisation of UK imaging practice. Substantial investment in radiology 
services including equipment, increased scanning capacity, staffing and training 
will be required in order to ensure all patients in the UK have the opportunity to 
benefit from advanced imaging techniques in the initial assessment of plasma 
cell malignancy.  
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